Approved for use through 07/31/2008, OMB 0651-2031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10082493			
Filing Date		2002-02-22			
First Named Inventor	Stept	phane Kasriel			
Art Unit		2157			
Examiner Name Abd		ıllahi Elmi Salad			
Attorney Docket Number		D33-024-01-US			

U.S.PATENTS							Remove	
Examiner Initial*	Cite No			Releva	Columns,Lines where nt Passages or Relevant s Appear			
	1	6912591		1988-03-01	Lash, Thomas D.			
	2	7058700		2006-06-06	Casalaina, Marc C.			
	3	7072987		2006-07-04	Jurisch et al.			
	4	7096418		2006-08-22	Singhal et al.			
	5	7092977		2006-08-15	Leung et al			
If you wis	h to a	dd additional U.S. Paten	t citatio	n information p	lease click the Add button.		Add	
			U.S.P	ATENT APPLI	CATION PUBLICATIONS		Remove	
Examiner Initial*	Cite No	Publication Number	Kind Publication Name of Patentee or Applicant of cited Document		Releva	Columns,Lines where nt Passages or Relevant s Appear		
	1	20030110186	A1	2003-06-12	Markowski et al.			

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10082493
Filing Date		2002-02-22
First Named Inventor Steph		nane Kasriel
Art Unit		2157
Examiner Name Abdu		llahi Elmi Salad
Attorney Docket Number		D33-024-01-US

	2	20020048450	A1	2002-0	4-25	Zetts, John Mark					
	3	20020161860	A1	2002-1	0-31	Godin et al.					
	4	20030120752	A1	2003-0	2003-06-26 Corcoran, Michael						
	5	20060168118	A1	2006-0	006-07-27 Godin et al.						
	6	20060168348	8348 A1 2006-07-27 Casalana, Marc C.								
If you wis	h to a	d additional U.S. Publi	shed Ap	plication	citatio	n information p	olease click the Ad	d butto			
				FORE	GN PA1	TENT DOCUM	ENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number ³						тя			
	1										
If you wis	h to a	d additional Foreign P	atent Do	cument	citation	information pl	lease click the Add	buttor	Add		_
			NON	I-PATE	NT LITE	RATURE DO	CUMENTS		Remove		
Examiner Initials*	Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (look, magazine, journal, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and							T5			
	**Active Cache: caching dynamic contents on the Web*, Pei Cao, Jin Zhang and Kevin Beach, The British Computer Society, The Institution of Electrical Engineers & IOP Publishing Ltd., 1999.										
If you wis	If you wish to add additional non-patent literature document citation information please click the Add button Add										

	Application Number		10082493	
INFORMATION DIGGS COURT	Filing Date		2002-02-22	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor	Named Inventor Stephane Kasriel		
(Not for submission under 37 CFR 1.99)	Art Unit		2157	
,	Examiner Name	Abdullahi Elmi Salad		
	Attorney Docket Number		D33-024-01-US	

EXAMINER SIGNATURE								
Examiner Signature		Date Considered						
*EXAMINER: Initial if citation if not in confo								

16c Kinc Codes of USPTO Patent Documents at www.ISPTO.GOV or MPEP 90104. 2 Enter office that issued the document, by the two-left to patent Southern Souther

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10082493	
Filing Date		2002-02-22	
First Named Inventor	Stephane Kasriel		
Art Unit		2157	
Examiner Name Abdu		llahi Elmi Satad	
Attorney Docket Number		D33-024-01-US	

CERTIFICATION STATEMENT

Please see 37	CFR 1.97 a	nd 1.98 to make the	he appropriate selection(s):
---------------	------------	---------------------	------------------------------

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 3.7 CFR 1.97(eVI.)

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no tend of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1/5(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1/9/(c)0.

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- ☐ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Shawn B Dempster/	Date (YYYY-MM-DD)	2006-10-06					
Name/Drint	Shown R Domnetor	Registration Number	34 321					

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 and 3T CFR.

1.14. This collection is estimated to take I hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, u.S. Operatment of Commence, P. O. Box 1430, Alexandriu, V.S. 2213.1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.A. 2213.1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is \$3 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiation.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, cuting an inspection of records concluded by GSAs a part of that apency's responsibility to recommend improvements in records management practices and programs, under suthority of 4d U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 12(b) or issuance of a patient pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application port to public insepticines or an issuand patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.